Total Funding
72
96
Total FundingSeries A raised
Growth Score
-4 pts
Heat Score
63 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
479
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Grant Hawthorne: CFO- Francesco Falciani: Head of Bioinformatics
About the Company
Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is
developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.
